Calliditas Therapeutics AB logo

CALT

Calliditas Therapeutics AB

$17.85

Earnings Summary

Revenue
$49.73Mn
Net Profits
$-207.05Mn
Net Profit Margins
-416.31%

Highlights

Revenue:

Calliditas Therapeutics AB’s revenue jumped +Inf% since last year same period to $49.73Mn in the Q1 2022. On a quarterly growth basis, Calliditas Therapeutics AB has generated 59.51% jump in its revenue since last 3-months.

Net Profits:

Calliditas Therapeutics AB’s net profit fell -65.04% since last year same period to $-207.05Mn in the Q1 2022. On a quarterly growth basis, Calliditas Therapeutics AB has generated 5.53% jump in its net profits since last 3-months.

Net Profit Margins:

Calliditas Therapeutics AB’s net profit margin jumped NaN% since last year same period to -416.31% in the Q1 2022. On a quarterly growth basis, Calliditas Therapeutics AB has generated 40.77% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Calliditas Therapeutics AB post its latest quarter earnings

EPS Estimate Current Quarter
-0.32
EPS Estimate Current Year
-0.32

Highlights

EPS Estimate Current Quarter:

Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current quarter stand at -0.32 - a 43.02% jump from last quarter’s estimates.

EPS Estimate Current Year:

Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current year stand at -0.32.

Key Ratios

Key ratios of the Calliditas Therapeutics AB post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Calliditas Therapeutics AB’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the Calliditas Therapeutics AB has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-06-30
-0.83
-0.62
25.61%
2023-02-23
-0.32
0
100%
2022-03-31
-0.75
-0.53
29.42%

Company Information

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Organisation
Calliditas Therapeutics AB
Headquarters
Kungsbron 1, D5, Stockholm, Sweden, 111 22
Employees
98
Industry
Health Technology
CEO
Renee J. Aguiar-Lucander

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*